来那度胺对非霍奇金淋巴瘤患者临床疗效与不良反应的影响

Effect of Lenalidomide on Clinical Efficacy and Adverse Reactions in Patients with Non-Hodgkin Lymphoma

目的:探讨来那度胺对非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)患者临床疗效与不良反应的影响。方法:选取2019年1月-2020年1月本院收治的NHL患者40例,依据不同用药方案将其分为对照组与研究组,每组20例。对照组进行R-CHOP方案治疗,研究组在对照组基础上加入来那度胺治疗。比较两组临床疗效、治疗前后血管内皮生长因子(VEGF)及炎性因子水平,比较两组不良反应发生情况。结果:研究组客观缓解率(ORR)高于对照组(P<0.05)。治疗后,研究组VEGF、白介素-6(IL-6)与肿瘤坏死因子-α(TNF-α)水平均低于对照组,而白介素-10(IL-10)水平高于对照组(P<0.05)。研究组不良反应发生率低于对照组(P<0.05)。结论:来那度胺可有效提升NHL患者的临床疗效,降低VEGF水平,抑制炎性反应,且药物不良反应率低,值得临床推广。

Objective:To explore the effect of Lenalidomide on the clinical efficacy and adverse reactions in patients with non-Hodgkin lymphoma (NHL).Method:A total of 40 NHL patients admitted to our hospital from January 2019 to January 2020 were selected and divided into the control group and the study group according to different drug regimen,20 patients in each group.The control group was treated with R-CHOP scheme,and the study group was treated with Lenalidomide on the basis of the control group.The levels of vascular endothelial growth factor (VEGF) and inflammatory factors before and after treatment were compared between two groups.The occurrence of adverse reactions was compared between two groups.Result:The objective remission rate (ORR) of the study group was higher than that of the control group (P<0.05).After treatment,the levels of VEGF,interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in the study group were lower than those in the control group,while the level of interleukin-10 (IL-10) was higher than that in the control group (P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group (P<0.05).Conclusion:Lenalidomide can effectively improve the clinical efficacy of NHL patients,reduce the level of VEGF,inhibit the inflammatory response,and the rate of adverse drug reactions is low,which is worthy of clinical promotion.